Tennr vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Healthcare fax automation AI extracting referral and authorization data into EHR workflows; eliminating manual fax processing for medical practices where 80% of communications are still faxed.
About
Tennr is an AI-powered healthcare operations platform that automates fax-based administrative workflows for healthcare providers — extracting data from incoming faxes (referrals, prior authorizations, lab results, patient records) and automatically routing, categorizing, and populating EHR workflows to eliminate the manual data entry that consumes significant administrative staff time at medical practices and health systems. Founded in 2021 and headquartered in New York, Tennr has raised approximately $18 million targeting the persistent problem of healthcare fax volume, as US healthcare still transmits approximately 80% of inter-provider communications via fax.\n\nTennr's AI system reads incoming fax documents, identifies the document type (referral, authorization request, clinical note), extracts key clinical data (patient name, DOB, diagnosis codes, requested procedures), and automatically creates the corresponding workflows in the practice management or EHR system — eliminating the need for front desk staff to manually read faxes, type data into multiple systems, and track follow-up actions. The platform integrates with major EHR systems (Epic, Athenahealth, eClinicalWorks) to push extracted data directly into the right fields.\n\nIn 2025, Tennr operates in the healthcare administrative AI market alongside Thoughtful AI (healthcare billing automation), Olive AI (now restructured), and general RPA platforms that healthcare organizations adapt for administrative workflows. The healthcare fax automation market is significant — large specialty practices can receive thousands of faxes daily, with each requiring manual processing. Tennr's AI-native approach for healthcare document understanding (trained specifically on medical fax content) differentiates it from generic document AI. The 2025 strategy focuses on expanding to more specialty practices, deepening integrations with more EHR platforms, and adding prior authorization automation as a high-value workflow.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.